OLD Republic International Corp Raises Position in Pfizer Inc. $PFE

OLD Republic International Corp lifted its stake in Pfizer Inc. (NYSE:PFE) by 20.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,963,700 shares of the biopharmaceutical company’s stock after buying an additional 340,000 shares during the quarter. Pfizer makes up about 1.9% of OLD Republic International Corp’s investment portfolio, making the stock its 26th largest position. OLD Republic International Corp’s holdings in Pfizer were worth $47,600,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Gould Capital LLC lifted its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the fourth quarter worth approximately $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Berenberg Bank cut their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Price Performance

PFE opened at $23.98 on Tuesday. The stock has a fifty day moving average of $24.76 and a 200-day moving average of $24.25. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a market capitalization of $136.34 billion, a P/E ratio of 12.76, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.